Cutting the dosage: micro-cap opioid biotech Avenue Therapeutics slashes IPO range by 40% – Nasdaq

Cutting the dosage: micro-cap opioid biotech Avenue Therapeutics slashes IPO range by 40%NasdaqAvenue Therapeutics, which is a Fortress Biotech spinoff developing an IV formulation of the opioid tramadol, lowered the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise $30 million by offering 5 … …read […]

from WordPress http://ift.tt/2s4PdXv
via IFTTT

Newer Post Older Post